Approved indications: Orally administered nitazoxanide is FDA‑approved for the treatment of acute diarrhea caused by Giardia lamblia or Cryptosporidium parvum in immunocompetent adults and children 1 year of age and older.

Off‑label uses and evidence: Clinicians sometimes use nitazoxanide off‑label for other protozoal infections (for example Entamoeba histolytica, Cyclospora, and Isospora), for persistent or immunocompromised cryptosporidiosis, and it has been studied for Clostridioides difficile infection and several viral illnesses (such as influenza and COVID‑19), but data for these uses are limited or mixed and they are not FDA‑approved indications.

Efficacy expectations: In approved indications, diarrhea often improves within 2–3 days of starting therapy, with clinical cure (resolution of diarrhea) in roughly 70–90% of patients and clearance of the parasite from stool in about 60–75%; compared with other antiparasitics like metronidazole or tinidazole, nitazoxanide provides similar cure rates with a short 3‑day course, is one of the few drugs with proven benefit in cryptosporidiosis for immunocompetent patients, and is generally well tolerated.

Typical adult dosing: For diarrhea caused by Giardia lamblia or Cryptosporidium parvum, adults and adolescents 12 years and older usually take 500 mg by mouth every 12 hours with food for 3 days (one 500‑mg tablet or 25 mL of 100 mg/5 mL oral suspension per dose).

Typical pediatric dosing:

• Age 1–3 years: 100 mg (5 mL of suspension) by mouth every 12 hours with food for 3 days.
• Age 4–11 years: 200 mg (10 mL of suspension) by mouth every 12 hours with food for 3 days.
• Age ≥12 years: same regimen as adults; 500‑mg tablets should not be used in children 11 years or younger because each tablet contains more drug than recommended for that age group.

How to take it: Take each dose with food to improve absorption and reduce stomach upset, shake the oral suspension well and measure doses with an oral syringe or marked dosing cup, and try to take the medicine at the same times every day; note that tablets and suspension are not bioequivalent, so follow the specific product instructions given by your prescriber or pharmacist.

Special dosing instructions: In people with weakened immune systems or unusually severe or persistent infections, an infectious‑disease specialist may adjust the duration or repeat the course as an off‑label strategy, based on clinical response and overall health.

Missed dose: If a dose is missed, take it as soon as you remember unless it is almost time for the next scheduled dose; if it is close to the next dose, skip the missed dose and resume your regular schedule—do not take two doses at once to make up for a missed dose.

Overdose: Very high single oral doses have generally caused no more than mild gastrointestinal symptoms in studies, but any suspected overdose should prompt immediate contact with a poison control center (1‑800‑222‑1222 in the U.S.) or emergency services for evaluation and supportive care.

Common side effects:

• Usually mild stomach‑related symptoms such as abdominal pain, nausea, vomiting, diarrhea, or heartburn, plus headache.
• Change in urine color (yellow to yellow‑green or darker) and occasionally mild yellow discoloration of the eyes, both typically harmless and reversible.
• These effects often begin within the first few doses and resolve soon after the 3‑day course ends.

Serious or rare adverse effects: Stop the drug and seek immediate medical care for signs of hypersensitivity or severe allergy (rash or hives, itching, swelling of face/lips/tongue, trouble breathing, chest tightness), severe or persistent vomiting or diarrhea causing dehydration, unusual bleeding or bruising, or new fast or irregular heartbeat.

Warnings and precautions: Use is contraindicated in anyone with a known hypersensitivity to nitazoxanide or product ingredients; safety of the oral suspension is not established in children under 1 year, and tablets are not recommended under 12 years; data in pregnancy are limited so use only if the expected benefit justifies potential risks; small amounts of active metabolite appear in breast milk and are unlikely to harm older infants, but an alternative drug may be preferred when breastfeeding newborn or preterm infants; effects in significant kidney or liver disease have not been well studied, so extra caution and clinical monitoring are advised; for people with HIV or other major immunodeficiency, nitazoxanide is less effective against Cryptosporidium and is not an approved indication.

Safety compared with similar drugs: For its short, 3‑day approved course, nitazoxanide has a favorable safety profile with mostly mild, self‑limited side effects, minimal evidence of liver toxicity, no known effect on heart rhythm (QT interval), and few pharmacokinetic drug–drug interactions compared with many other anti‑infective agents.

Reporting side effects and safety updates: Patients and caregivers can report suspected adverse effects to the FDA MedWatch program (online or by calling 1‑800‑FDA‑1088), and clinicians should consult the most recent product label and FDA safety communications for up‑to‑date warnings and recommendations.

Major drug interactions:

• The active metabolite tizoxanide is more than 99.9% bound to plasma proteins, so nitazoxanide can increase the free (active) levels of other highly protein‑bound, narrow‑therapeutic‑index medicines such as warfarin or phenytoin; clinicians often avoid concurrent warfarin or monitor INR or drug levels closely and adjust doses if these drugs must be used together.
• In vitro studies show tizoxanide does not significantly inhibit or induce cytochrome P450 enzymes, so clinically important interactions via CYP‑mediated metabolism are unlikely with most other drugs.

Other medicines, foods, and alcohol: No specific interactions are known with most common prescription or OTC medicines, supplements, or foods, but food substantially increases absorption, so doses should always be taken with meals; there is no specific contraindication with alcohol, but drinking alcohol can worsen dehydration or gastrointestinal upset in people with diarrhea, so limiting or avoiding alcohol during treatment is usually recommended.

Precautions with medical conditions and co‑medications: Use caution in patients with significant liver or kidney impairment (because pharmacokinetics have not been well characterized), in those with diabetes who are taking the sucrose‑containing oral suspension, and in people with HIV or other immunodeficiency, in whom nitazoxanide is less effective for Cryptosporidium and should generally be managed by a specialist.

Monitoring needs: For a standard 3‑day course in otherwise healthy patients, routine blood tests are usually unnecessary; when nitazoxanide is used together with warfarin or other highly protein‑bound drugs, or when taken for prolonged or off‑label regimens, clinicians may monitor INR, relevant drug concentrations, and occasionally liver function tests based on the overall risk profile.

Q: How long does it take for nitazoxanide to start working on my diarrhea?
A: Many people notice some improvement within 1–3 days, and the full 3‑day course is usually enough to stop the diarrhea; if symptoms are not clearly improving after finishing treatment, or if you cannot keep fluids down, contact your healthcare provider.

Q: Do I really need to take nitazoxanide with food?
A: Yes, taking nitazoxanide with a meal significantly improves how much medicine your body absorbs and often reduces stomach upset, so you should not take it on an empty stomach.

Q: Can nitazoxanide be used to treat flu or COVID‑19?
A: Nitazoxanide has shown activity against some viruses in laboratory and early clinical studies, but in the United States it is not FDA‑approved for any viral infection, and it should not replace recommended vaccines or standard antiviral treatments for influenza or COVID‑19.

Q: Is nitazoxanide safe during pregnancy or while breastfeeding?
A: Human data in pregnancy are limited and the drug is used only when the expected benefit outweighs possible risks; small amounts of active metabolite appear in breast milk and are unlikely to harm older infants, but an alternative medicine is often preferred for mothers nursing newborn or preterm babies, so decisions should be made with your obstetric or pediatric clinician.

Q: Why has my urine (and sometimes the whites of my eyes) changed color on this medicine?
A: Nitazoxanide’s metabolites can harmlessly tint the urine yellow to yellow‑green and occasionally cause a mild yellow discoloration of the eyes that resolves after the drug is stopped, but if you also develop very dark urine, pale stools, intense itching, or yellowing of the skin, you should seek medical care to rule out other causes.

Storage: Store nitazoxanide tablets and powder for oral suspension at room temperature (68–77°F / 20–25°C), in the original tightly closed container, away from heat, moisture, and light; after the suspension is mixed, keep it at room temperature and discard any unused portion after 7 days.

Disposal: Keep all forms out of the reach of children and pets, use a medicine take‑back program if available, or if local guidance allows, mix leftover liquid or crushed tablets with an undesirable substance (such as coffee grounds or cat litter), seal in a bag or container, and place in the household trash; do not flush unless specifically instructed on the product label or by a pharmacist.